UAE Initiative Expands Access to Liquid Biopsy Testing for Advanced Non-Small Cell Lung Cancer Patients

Non-small cell lung cancer accounts for around 80–85 per cent of lung cancer cases worldwide, making it the most common type of the disease.

Doctors say early and precise diagnosis plays an important role in deciding the right treatment plan.

Liquid biopsy is a blood-based test that helps identify genetic changes in cancer cells. This information can guide doctors in choosing treatments that are better suited to each patient.

Under the initiative, testing will be carried out using technology from Guardant Health, which specialises in cancer…